Generics REMS Hurdles Lowered Somewhat By FDA Protocol Letters
This article was originally published in PharmAsia News
Executive Summary
But the U.S. FDA still cannot force brand firms to provide products for bioequivalence testing, which may limit the policy’s ability to remove a barrier that generic firms allege some NDA sponsors use to block competition.